The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Tirabrutinib, a second-generation BTKi, in the treatment of symptomatic WM and Bing-Neel syndrome
Naohiro Sekiguchi, MD, PhD, National Hospital Organization Disaster Medical Center, Tachikawa, Japan, presents data from a Phase II trial investigating tirabrutinib, a second-generation BTK inhibitor (BTKi), in symptomatic Waldenström’s macroglobulinemia (WM). He also mentions its potential use for treating Bing-Neel syndrome, with various case reports showing it penetrates the blood-brain barrier. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Tirabrutinib is developed from Japan. It’s a second generation Bruton’s tyrosine kinase inhibitor. We conducted a Phase II study of tirabrutinib monotherapy for symptomatic Waldenstrom’s patients. 27 patients enrolled on the study and with a median follow-up duration of two years the major response rate was 93% and two-year progression-free survival was 92% and overall survival is 100%...
Tirabrutinib is developed from Japan. It’s a second generation Bruton’s tyrosine kinase inhibitor. We conducted a Phase II study of tirabrutinib monotherapy for symptomatic Waldenstrom’s patients. 27 patients enrolled on the study and with a median follow-up duration of two years the major response rate was 93% and two-year progression-free survival was 92% and overall survival is 100%. So regarding toxicity, it’s very safe and as for hypertension, bleeding tendency, and arrythmia, it’s very limited. On the other hand very mild skin-related adverse event is recognized in about half but we can easily manage them. And as for the tirabrutinib for Bing-Neel syndrome it’s a very interesting topic for now and we have many case reports treated by tirabrutinib for Bing-Neel syndrome and the penetration rate of the tirabrutinib into the blood-brain barrier is very high, 13 to 18 percent according to the report from the tirabrutinib for primary CNS lymphoma relapsed refractory cases.
Read more...
Disclosures
Honoraria: Janssen, Ono; Research funding: Incyte Biosciences Japan, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, Ono.
